Efectividad de la terapia con linfocitos infiltrantes tumorales en persones con melanoma metastásico: revisión bibliográfica
Text Complet
Compartir
Introduction: In recent years, there has been an increase in the incidence of cutaneous
melanoma, which has resulted in an increase in mortality associated with this disease. Recently,
treatment options have been slim, with chemotherapy and, in certain cases, IL-2, the only
available and recognized options. However, immunotherapy has emerged as a hopeful
alternative, due to the discovery of the relationship between the tumor and the cells of the
individual's immune system, which may be crucial for the course of the disease, showing
substantial improvements in the survival of individuals with melanoma in advanced stages.
Objective: Provide scientific evidence on the use of tumor-infiltrating lymphocyte therapy as a
treatment for metastatic melanoma.
Material and methods: An exhaustive bibliographic review has been carried out using the
PubMed and Elsevier databases during the months of January to April 2024. The search has
been limited to studies published in English between 2018 and 2024. After applying the criteria
inclusion and exclusion, a total of 10 articles were selected for analysis in this study.
Results: The selected studies support that tumor-infiltrating lymphocyte therapy shows
response rates greater than 60% compared to other available T cell therapies. The therapy has
also been observed to lead to an improvement in overall survival and disease progression.
Conclusion: The results of the literature review support the effectiveness of treatment with
tumor-infiltrating lymphocytes in patients with metastatic melanoma. However, some problems
arise that require attention, such as the need for phase II and III clinical trials, improve the
method and expansion time of TILs, as well as provide training to professionals involved in this
therapy